Kynamro, also known as mipomersen, is a medication used to treat a rare genetic condition called homozygous familial hypercholesterolemia (HoFH). This condition causes extremely high levels of low-density lipoprotein (LDL) cholesterol in the blood, leading to an increased risk of heart disease and other cardiovascular complications.

Kynamro works by inhibiting the production of a protein called apolipoprotein B, which is responsible for transporting LDL cholesterol in the blood. By reducing the levels of this protein, Kynamro helps to lower LDL cholesterol levels and decrease the risk of heart disease in patients with HoFH.

It is important to note that Kynamro is not a first-line treatment for high cholesterol and is only prescribed for patients with HoFH who have not responded to other cholesterol-lowering medications. It is typically used in combination with a healthy diet and lifestyle changes to achieve optimal results.

As with any medication, Kynamro may cause side effects in some patients. Common side effects include injection site reactions, flu-like symptoms, and liver abnormalities. It is important to discuss any concerns or potential side effects with your healthcare provider before starting treatment with Kynamro.

Overall, Kynamro is a valuable treatment option for patients with HoFH who have not had success with other cholesterol-lowering medications. By working to lower LDL cholesterol levels and reduce the risk of heart disease, Kynamro can help patients with HoFH live healthier, longer lives.